Hola Walter,
Bienvenido al foro! Claro que has hecho bien en abrir un tema! ;-)
Siento mucho tu situación. Entiendo perfectamente por lo que estás pasando, pues yo empecé con síntomas a mis 21 años…
Dentro de todo lo malo, la buena noticia es que tu edad juega a tu favor en cuanto a recuperación se refiere. Así que mucho ánimo.
A tu mensaje:
1- Primero, y fuera del tema, preguntarte si tienes amalgamas dentales. De ser así te aconsejaría que leyeses la información de la web de http://www.mercuriados.org" onclick="window.open(this.href);return false;, pues es el paso fundamental para pensar en una mejoría.
2- Respecto a la Naltrexona, pues tienes “suerte” de tener dolor. Si te diagnostican Fibromialgia, entonces lo tienes más fácil. Llévale a tu médico estos dos estudios. En el primero se muestra cómo la naltrexona en dosis bajas (lo que conocemos como LDN) mejora en un 30% los síntomas de la FM, con respecto al placebo (o sea que la mejoría es más alta) en sólo varios meses. El segundo estudio demuestra cómo la naltraxona en dosis altas, es decir, actuando como inhibidor opiáceo, NO funciona para la FM. Esto deja claro que la Naltrexona funciona, y que lo hace en dosis bajas…Debería ser suficiente para que te la prescriban.
Como último recurso puedes apelar al efecto placebo. Es lo que hice yo! ;-)
Mucha suerte y cuéntanos, ¿vale?
S.
1: Pain Med. 2009 May-Jun;10(4):663-72. Epub 2009 Apr 22. Links
Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study.
Younger J, Mackey S.
School of Medicine, Department of Anesthesia, Division of Pain Management, Stanford University, 780 Welch Road, Suite 208, Palo Alto, CA 94304-1573, USA.
[email protected]
OBJECTIVE: Fibromyalgia is a chronic pain disorder that is characterized by diffuse musculoskeletal pain and sensitivity to mechanical stimulation. In this pilot clinical trial, we tested the effectiveness of low-dose naltrexone in treating the symptoms of fibromyalgia. DESIGN: Participants completed a single-blind, crossover trial with the following time line: baseline (2 weeks), placebo (2 weeks), drug (8 weeks), and washout (2 weeks). PATIENTS: Ten women meeting criteria for fibromyalgia and not taking an opioid medication. INTERVENTIONS: Naltrexone, in addition to antagonizing opioid receptors on neurons, also inhibits microglia activity in the central nervous system. At low doses (4.5 mg), naltrexone may inhibit the activity of microglia and reverse central and peripheral inflammation. OUTCOME MEASURES: Participants completed reports of symptom severity everyday, using a handheld computer. In addition, participants visited the lab every 2 weeks for tests of mechanical, heat, and cold pain sensitivity. RESULTS: Low-dose naltrexone reduced fibromyalgia symptoms in the entire cohort, with a greater than 30% reduction of symptoms over placebo. In addition, laboratory visits showed that mechanical and heat pain thresholds were improved by the drug. Side effects (including insomnia and vivid dreams) were rare, and described as minor and transient. Baseline erythrocyte sedimentation rate predicted over 80% of the variance in drug response. Individuals with higher sedimentation rates (indicating general inflammatory processes) had the greatest reduction of symptoms in response to low-dose naltrexone. CONCLUSIONS: We conclude that low-dose naltrexone may be an effective, highly tolerable, and inexpensive treatment for fibromyalgia.
PMID: 19453963
Effects of Naltrexone on Pain Sensitivity and Mood in Fibromyalgia: No Evidence for Endogenous Opioid Pathophysiology
Jarred W. Younger,1* Alex J. Zautra,2 and Eric T. Cummins3
1Department of Anesthesia, Stanford University School of Medicine, Palo Alto, California, United States of America
2Department of Psychology, Arizona State University, Tempe, Arizona, United States of America
3College of Medicine, University of Arizona, Tucson, Arizona, United States of America
William Taylor, Editor
University of Otago, New Zealand
* E-mail:
[email protected]
Conceived and designed the experiments: JWY AZ. Performed the experiments: JWY EC. Analyzed the data: JWY. Contributed reagents/materials/analysis tools: JWY. Wrote the paper: JWY AZ EC.
Received January 29, 2009; Accepted March 16, 2009.
Abstract
The pathophysiological mechanisms underlying fibromyalgia are still unknown, although some evidence points to endogenous opioid dysfunction. We examined how endogenous opioid antagonism affects pain and mood for women with and without fibromyalgia. Ten women with fibromyalgia and ten age- and gender-matched, healthy controls each attended two laboratory sessions. Each participant received naltrexone (50mg) at one session, and placebo at the other session, in a randomized and double-blind fashion. Participants were tested for changes in sensitivity to heat, cold, and mechanical pain. Additionally, we collected measures of mood and opioid withdrawal symptoms during the laboratory sessions and at home the night following each session. At baseline, the fibromyalgia group exhibited more somatic complaints, greater sensory sensitivity, more opioid withdrawal somatic symptoms, and lower mechanical and cold pain-tolerance than did the healthy control group. Neither group experienced changes in pain sensitivity due to naltrexone administration. Naltrexone did not differentially affect self-reported withdrawal symptoms, or mood, in the fibromyalgia and control groups. Consistent with prior research, there was no evidence found for abnormal endogenous opioid activity in women with fibromyalgia.
PMID: 19365548 [PubMed - indexed for MEDLINE]
"Aquel que tiene un porqué para vivir se puede enfrentar a todos los cómos" F. Nietzsche
"Sometimes it's the people who no one imagines anything of who do the things that no one can imagine"